Bioventus Extends Distribution Agreement for SUPARTZ FX Viscosupplement

Bioventus entered into an agreement with Seikagaku to continue U.S. distribution of SUPARTZ FX™ viscosupplement through May 2019, following expiration of current terms in May 2017.

Seikagaku and Bioventus had entered into an exclusive agreement for U.S. distribution of SUPARTZ® injectable treatment for knee OA pain in 1Q12.

In 4Q15,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us